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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To investigate the effects of dihydrocodeine (DHC) in comparison to other pharmaceutical opioids and placebos in the detoxification
of opiate-dependent individuals, as well as in maintenance substitution therapy.
B A C K G R O U N D
Description of the condition
According to the World Drug Report (2014), between 162 mil-
lion and 324 million people (3.5 per cent and 7.0 per cent of the
world population aged 15 to 64 years) in 2012 had used an illicit
drug at least once in the previous year, with an estimated 183,000
(range: 95,000 to 226,000) drug-related deaths (UNODC 2014).
This corresponds to a mortality rate of 40.0 (range: 20.8 to 49.3)
deaths per million among the population in this age range. Prob-
lem drug use remained stable at between 16 and 39 million in-
dividuals in this reporting period. Injecting drug use is estimated
by the United Nations Office on Drugs and Crime (UNODC),
the Joint United Nations Programme on HIV/AIDS (UNAIDS),
the World Bank and the World Health Organization (WHO), as
ranging between 8.9 million and 22.4 million, and with an esti-
mated prevalence rate of 0.27 per cent (range: 0.19 to 0.48 per
cent) of the population aged 15 to 64 years (UNODC 2014). In
addition to related social, economic and law enforcement costs,
injecting risk behaviours contribute to HIV and hepatitis C vul-
nerability and transmission. Harm reduction services act as a ma-
jor component in global tactics and responses to the spread of
HIV, and include needle and syringe programmes, opioid sub-
stitution therapy, HIV testing and counselling, and antiretroviral
therapy (UNODC 2014). According to the World Health Bul-
letin in 2011, governments of countries in which injecting drug
use and HIV epidemics represent a public health problem are in-
creasingly preoccupied with alternative opioid substitution ther-
apy modalities, within integrated HIV prevention and treatment
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programmes (Kermode 2011).
There are an estimated 15.5 to 15.6 (WHO)million people world-
wide aged 15 and older who are dependent on illicit opiates
(Degenhardt 2014; WHO 2009), which is an estimated preva-
lence of 0.14% for males and 0.30% for females. In 2007 it was
estimated that 7 million of these individuals use heroin (UNODC
2007). In terms of illicit opiates and opioids, recent global trends
indicate displacement between pharmaceutical and/or prescrip-
tion opioids and heroin, dependent on pricing, availability and
access in illicit drug markets (UNODC 2014). Opioid depen-
dence is estimated to account for 9.2 million disability-adjusted
life years lost (DALYs) worldwide in 2010, which is 0.37% of the
total DALYs lost worldwide (Degenhardt 2014). The burden in-
creased 73% in 10 years (from 1990 to 2010). Seven million of
these DALYs were lost due to disability (YLD), which accounts
for almost half (43.7%) of YLDs that are attributed to illicit drug
use disorders in total and 0.94% of all YLDs worldwide. In addi-
tion, 2 million years of life lost are estimated to be due to opioid
dependence (Degenhardt 2014). In 2010 alone, a total of 43,000
deaths were attributed to illicit opiate dependence (Degenhardt
2014).
Opiate dependence develops following the regular use of opioids,
and is defined as a chronic, relapsing disorder and permanent
metabolic deficiency (Dole 1965) and contributes to compulsive
drug-seeking behaviours, difficulties in controlling consumption,
awithdrawal state upon reductionor cessation, and evidence of tol-
erance, despite destructive physical and psychosocial consequences
for the user (WHO 2009). Opiate dependence is characterised by
three or more of the following features occurring together in the
previous year of use:
• a strong desire or sense of compulsion to take opioids,
• difficulties in controlling opioid use,
• a physiological withdrawal state,
• tolerance,
• progressive neglect of alternative pleasures or interests
because of opioid use, and
• persisting with opioid use despite clear evidence of overtly
harmful consequences (WHO 2007).
Opiate dependence incurs health, social, law enforcement and eco-
nomic costs. In terms of health, illicit opioid use is a major causal
factor in mortality from both intoxication (overdose, driving acci-
dents), and transmission of blood-borne disease via injecting risk
behaviours (Degenhardt 2011). The primary cause of death for
opiate users is overdose (UNODC 2013). Although data are lim-
ited, it is estimated that 70,000 to 100,000 people die from opi-
oid overdose every year (UNODCWHO 2013). Other causes of
death include trauma (including violence and homicide, injuries
and accidents), suicide, and liver- and respiratory-related disease
(Darke 2002;Darke 2012;Degenhardt 2011;Vlahov2004). Illicit
opiate users often inject their drugs, which is strongly related to
HIV transmission. An estimated 5% to 10%ofHIV transmissions
are estimated to be due to injecting drug use, often of an opiate
such as heroin. In some parts of the world, this is as high as 40%
(Mathers 2010). A recent systematic review also found that AIDS-
related mortality was 1.88 per 100 person years across studies con-
ducted in Asia, Europe (central and western), North America and
Australasia (Degenhardt 2011). Unsafe injecting practices associ-
ated with illicit opiate use have also been associated with hepatitis
C transmission, with an estimated 3 to 4 million people newly
infected every year and 90% of these new infections attributable
to unsafe injection practices (Hellard 2009).
In addition, opiate dependence can cause harm beyond the indi-
vidual who uses opiates. The use of illicit opiates such as heroin
and morphine among opiate-using pregnant women can have se-
rious effects for their unborn babies including spontaneous abor-
tion and infant mortality. Opiates are also transferrable to the foe-
tus and change the placental function, making preterm delivery a
strong possibility. Babies can be born with congential issues, and
experience withdrawal from opiates (Malek 2012). Neonatal ab-
stinence syndrome (NAS), which is the withdrawal from opioids
of a newborn baby, is a well-established phenomenon (Finnegan
1975). It may last up to 10 weeks after delivery and require that
the affected child-to-be is placed in the intensive care unit, be-
cause if they are untreated this can lead to increased risk of infant
mortality (Jansson 2009; Malek 2012). This may have significant
costs for healthcare services (Patrick 2012).
Description of the intervention
Evidence has shown that opioid substitution therapy programmes
are effective in reducing illicit opiate use, HIV-related risk be-
haviours, fatal overdose and criminal activity, and associated fam-
ily, community and financial stress. They also enhance access to
and continued use of medical and social services in both ado-
lescents (Minozzi 2014) and adults (Ferri 2011; Gowing 2011;
Lawrinson 2008;Mattick 2014;Weber 2009), including pregnant
women (Minozzi 2013). Despite this evidence of effectiveness,
it is estimated globally that only 8% of injecting drug users re-
ceive opioid substitution therapy, with lower figures in developing
countries (Mathers 2010).
Opiate users often present to community and specialist services
requesting detoxification (Oldham 2004). Approaches to assist
and support individuals who are dependent on opiates include
detoxification, relapse prevention programmes, outpatient coun-
selling, therapeutic communities and long-term opiate substitu-
tion (Amato 2005; Amato 2011). Treatment and detoxification
using various therapeutic agents is vital in the management of pa-
tients dependent on opiates. Agents include oral administration
of full or partial opioid agonists (i.e. methadone, buprenorphine,
levomethadyl acetate (LAAM), codeine or oral morphine) (Amato
2005; Gowing 2011; Riksheim 2014). Methadone maintenance
treatment is the most frequently prescribed treatment worldwide.
One exception is in France where greater proportions of patients
are prescribed buprenorphine (Auriacombe 2004).
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Methadone maintenance treatment has been extensively studied,
showing strong evidence for its effectiveness in recent Cochrane
reviews (Mattick 2009; Mattick 2014). Calls to scale up availabil-
ity of methadone maintenance treatment have been evident in re-
cent years (Mathers 2010; Mattick 2009). Low threshold metha-
done maintenance treatment is increasingly popular and designed
to: attract a wider range of patients; reduce barriers to admission;
improve retention of patients in treatment; and reduce heroin
use, injecting risk behaviours, criminal activity and mortality rates
(Strike 2013). Retention in treatment outcomes are related to ap-
propriate and higher doses of methadone and individualisation
of doses (Amato 2005; Bao 2009). However, methadone main-
tenance treatment remain controversial due to its indefinite and
often long-term provision of dependence-producing medication
(Amato 2005; Sees 2000).
Buprenorphine is also effective as a maintenance treatment agent,
with comparisons to methadone in a Cochrane review conclud-
ing that both are effective in the maintenance treatment of heroin
dependence, retention of patients in treatment at any dose above
2 mg, and suppression of illicit opioid use at doses of 16 mg or
higher (Mattick 2014). However, this Cochrane review suggests
that compared tomethadone, buprenorphine results in poorer pa-
tient retention in treatment when doses are flexible or at low fixed
doses. On the other hand, Maas 2013 advises the provision of
buprenorphine as appropriate if the primary outcomes of treat-
ment are stopping opiate use, as well as maintaining abstinence.
Buprenorphine may cause fewer fatal intoxications than meth-
adone (Soyka 2015). Comparisons between buprenorphine and
methadone at fixed medium or high doses show that effectiveness
relating to treatment retention and suppression of illicit opioid
use appear similar (Mattick 2009). Of note is that flexible doses of
these agents are more cost effective and applicable to patient care
(Connock 2007), and that methadone is superior in retaining pa-
tients in treatment (Mattick 2014). Costs of methadone provision
are also lower than those for buprenorphine (Maas 2013).
Recent studies have underscored the effects of varied aspects of
these substitution programmes and the interplay of individual pa-
tient factors (Arora 2013; Riksheim 2014; Strike 2013). Other
concerns centre on the safety and effectiveness of methadone and
buprenorphine in specific patient subgroups (Connock 2007). Of
note is that the presence of adjunct psycho-social support and
treatment do not incur additional benefits to treatment outcomes,
and highlight the need for employing varied criteria in assessment
of treatment outcomes as they relate to individual, interpersonal,
vocational, health and emotional functioning, and subsequent rec-
ommendations (Amato 2011; Davoli 2015). Alternatives include
heroin substitution treatment, with Cochrane reviews suggesting
the prescribing of heroin alongside flexible doses of methadone is
a feasible option for long-term treatment-refractory opioid users
who have a history of failed maintenance treatment (Ferri 2011).
Use of slow release oral morphine (SROM) has also been assessed
in several small trials but there is not sufficient evidence to show
that it is effective, and there have also been reports of adverse events
(Ferri 2013).
A Cochrane review comparing treatments for opiate with-
drawals found no significant differences between methadone and
buprenorphine in treatment completion, but faster reduction of
withdrawal symptoms with buprenorphine, and with buprenor-
phine more effective than clonidine in the management of opi-
oid withdrawal (Gowing 2009). Given positive retention rates of
methadone maintenance treatment in comparison to detoxifica-
tion programmes, studies have reported low support for diverting
resources frommethadone maintenance towards long-term detox-
ification (Sees 2000). Methadone has a long half-life and when
tapering employs incremental dose reductions over a course of 7 to
21 days. However patients report unpleasant withdrawals in later
stages of detoxification, giving rise to the increased use of alterna-
tives such as clonidine, lofexidine and dihydrocodeine (DHC) to
assist. Clonidine and lofexidine are more effective than placebo in
withdrawal management (Gowing 2014). Complications caused
by clonidine’s hypotensive and sedative effect and lofexidine’s lim-
ited capacity to manage withdrawals have reduced their popularity
in primary and community care settings (Seivewright 2000). Slow
tapering with temporary substitution of long-acting opioids can
reduce severity of withdrawals (Amato 2013). Antagonist-induced
withdrawal under heavy sedation or anaesthesia as a detoxifica-
tion option lacks value due to cost, the potential for adverse life-
threatening events, and required intensive care resources (Gowing
2010).
Not much is known about how DHC works in comparison to
other pharmacological interventions that are commonly used. It is
suggested, however, that DHC is a short-acting opioid (Banbery
2000), and therefore will need to be administered more frequently,
up to a few times a day (Banbery 2000;Hall 2007). DHC has been
proposed as a substitute for long-acting opioids such asmethadone
in order to assist with withdrawal symptoms (Banbery 2000). It
is also proposed that switching from long-acting opioids such as
methadone to DHC after detoxification can be used during the
detoxification process (Day 2003).
How the intervention might work
DHC is a semi-synthetic opioid analogue of codeine (Klepstad
2005) and a short-acting drug which offers an alternative substitu-
tion treatment and detoxification support to individuals with less
severe dependence on opiates, and to stabilise methadone patients
(Banbery 2000; Krausz 1995; Krausz 1998). DHC is well toler-
ated orally and has a half-life of about 4 hours (Banbery 2000). In
addition to its viable uses as an alternative tomethadone treatment
(Banbery 2000; Hall 2007; Krausz 1995; Krausz 1998), it is also
commonly prescribed as an antitussive, anti-diarrhoeal agent and
analgesic drug in the treatment of moderate pain (Leppert 2010;
Moore 2000; Webb 2001).
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DHC maintenance treatment is typically low threshold, less bu-
reaucratic, increases patient choice and retention in treatment, and
may be prescribed by general practitioners in the form of capsules
and juice for dispensing at pharmacies (Krausz 1998). Banbery
2000 reports that DHCmay have advantages in detoxifying meth-
adone-maintained patients in a rapid two-week outpatient detoxi-
fication programme by successfully using DHC to cross-over from
a methadone dose (30 mg). They report that, on consecutive use,
a “steady-state” condition for DHC is achieved and weaning can
be accomplished successfully with minimal complications within
a few days.
However, in contrast to methadone and buprenorphine, DHC
may be compromised by its short-acting properties, necessitat-
ing frequent dosing and risk of patients oscillating between seda-
tion and withdrawals (Backmund 2001; Banbery 2000; Seymour
2001; Strang 2005). PrescribedDHC is often inadequate in reliev-
ing acute opiate withdrawals (Tompkins 2007). The importance
of reducing periods of relative withdrawal between doses is thus
emphasised (Mitchell 2003), along with the need for experienced
prescribing practitioners in detoxification using DHC (similar to
methadone) (Bao 2009).
Why it is important to do this review
The most recent World Drug Report (UNODC 2014) has high-
lighted gaps in service provision for problem drug users receiving
access to drug dependence treatment, both in the community and
in more specialised settings such as prisons. DHC’s efficacy and
effectiveness as substitution therapy and its use for detoxification
is controversial (Banbery 2000; Ulmer 1997; Zamaprutti 2010)
and debate centres on its potential for use as treatment and detox-
ification for specific individuals with less severe dependence on
opiates and for stabilised methadone patients (Luty 2004). Dis-
satisfaction with the long half-life of methadone has stimulated
patient interest in alternative forms of short-term detoxification,
such as the use of short-acting drugs like DHC (Oldham 2004). If
DHC is shown to be effective as a short-term detoxification treat-
ment in community and special settings, it may well be a more
cost-effective option for governments than the long-term use of
methadone.
There have not beenmany studies on the possibility of usingDHC
as an alternative to other pharmacological interventions. There
is some evidence on the usefulness of DHC in managing opiate
withdrawals for individuals in police custody (Pearson 2000), and
on its safety, flexibility, potential retention of patients in treatment
and its capacity to reach wider groups of stabilised or low-thresh-
old drug users who use opiates (Krausz 1998; MacLeod 1998;
Robertson 1990; Swadi 1990). However, these studies are dated
and there is a need for a more systematic review of the evidence.
Given the potential for use in treating such wider groups of drug
users, particularly those with lower severity of opiate dependence,
accessing community care and general health settings, and as an
alternative for use in developed and developing countries, DHC
could present a useful alternative for short-term detoxification of
individuals in the community or be provided as an alternative
within specific settings such as prisons. A systematic review of the
evidence also indicates the need for experienced prescribing prac-
titioners in detoxification using DHC (Arora 2013), where there
are no existing guidelines on standard use, as well as studies to
establish whether it is feasible for maintenance therapy.
O B J E C T I V E S
To investigate the effects of dihydrocodeine (DHC) in compari-
son to other pharmaceutical opioids and placebos in the detoxifi-
cation of opiate-dependent individuals, as well as in maintenance
substitution therapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). Pre- and post-test studies
and qualitative studies will be excluded from this review.
Types of participants
Participants are adolescent (aged 16 years and older) and adult
individuals who are currently dependent on illicit opiates (heroin,
opium and illegally-sourced opiates such as morphine and
codeine), diagnosed according to the DSM (III, IV or V) criteria.
Participants who have pre-existing conditions (psychiatric con-
ditions, pregnancy) will be excluded. Individuals who have con-
traindications to DHC or the comparison pharmacological inter-
vention will also be excluded.
Types of interventions
Experimental intervention:
DHC as dispensed to participants primarily for detoxification
from opioid-agonist treatments, and secondarily for maintenance
purposes. Since DHC is a short-acting opioid, treatment may ini-
tially need to be provided every four hours (Hall 2007). In addi-
tion, because there are no regulations for the provision of DHC
as substitution therapy, there may be marked differences in the
dispensing of DHC (NICE 2007; Strang 2005). However, it is ex-
pected that detoxification will last up to 15 days, and maintenance
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for a minimum of 30 days, based on previous studies of opiate-
substitution therapy.
Control intervention:
The control could either be treatment as usual, placebo or other
types of pharmacological intervention. These include full (meth-
adone, levomethadyl acetate or LAAM, oral morphine) or partial
opioid antagonists (buprenorphine), as well as other medication
such as Alpha 2 adrenergic agonists (clonidine and lofexidine) and
antagonist medication (naltrexone).
Types of outcome measures
Primary outcomes
1. Treatment retention at the end of treatment and at follow-
up appointments (since dropout is a major problem in the
treatment of illegal opioids).
2. Abstinence from illicit opiate use after detoxification
therapy following the detoxification process at follow-up
appointments, either through self-report or urinalysis, measured
as the number of subjects abstinent at the end of treatment and
at follow up.
3. Abstinence from illicit opiate use after substitution/
maintenance therapy at follow-up periods, either through self-
report or urinalysis, measured as the number of subjects
abstinent at the end of treatment and at follow up.
4. Number of participants who experienced serious adverse
events. According to the guidelines, serious events include events
that result in death, are life-threatening, require hospitalisation
or an extension of existing hospitalisation, result in persistent or
significant disability or incapacity, result in congenital problems
or any other event that may put the participant’s health in
jeopardy and may require medical or surgical intervention to
prevent this (OHRP 2007). This includes the development of
drug abuse or dependency on DHC.
5. Number of participants who experienced adverse events.
Including any unfavourable medical occurrences that
participants experience at least partly due to their participation
in the study. This includes both physical and psychological
events (OHRP 2007).
Secondary outcomes
1. Use of other substances of abuse (both legal and illegal).
2. Engagement in crime.
3. Physical health consequences (typically related to substance
use such as appetite, levels of energy, nausea).
4. Drug overdose (symptoms of overdose and not limited to
death due to overdose).
5. Diversion (selling of drugs, use of prescribed opiates for
illegal use).
6. Education or employment status.
Search methods for identification of studies
Electronic searches
We will undertake a comprehensive search of the following
databases:
• Cochrane Drugs and Alcohol Group (CDAG) Specialised
Register (most recent);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (most recent);
• MEDLINE (PubMed) (January 1966 to present);
• EMBASE (Elsevier, EMBASE.com) (January 1974 to
present);
• Web of Science (Thomson Reuters) (January 1990 to
present).
A detailed search strategy will be developed inCENTRAL andwill
then be revised accordingly for each database that will be searched
to take into account differences in controlled vocabulary and syn-
tax rules. The search strategy will combine the subject search with
the Cochrane Highly Sensitive Search Strategy (CHSSS) for iden-
tifying randomised trials, as referenced in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
The subject search will utilise a combination of controlled vocab-
ulary and free-text terms based on the search strategy for searching
CENTRAL (see Appendix 1).
Searching other resources
We will also contact authors and search reference lists in all rele-
vant journal articles to obtain information on potential additional
RCTs. In addition, the authors will also search for other unpub-
lished studies and assess relevant conference proceedings for addi-
tional references. The following websites will also be searched:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/);
• Trialsjournal.cm.
All studieswith anEnglish abstract, whether or not the full article is
in a foreign language, will be included in the search. If, after reading
the abstract, the article appears to possibly meet the inclusion
criteria, it will be obtained and translated into English.
Data collection and analysis
Selection of studies
5Dihydrocodeine for detoxification and maintenance treatment in illicit opiate-dependent individuals (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Two authors (TC, IN) will independently inspect the titles and
abstracts that are found in the searches. Potentially-relevant arti-
cles will be obtained in full text and further assessed for eligibil-
ity by the same two review authors. Where there is any disagree-
ment between these two authors that cannot be resolved following
their independent review of the full text, another author (MCVH)
will read the studies in order to assist with making a decision on
whether to include or exclude the article.
Data extraction and management
Two of the review authors (TC and MCVH) will independently
extract data from the included studies using a data extraction form
that will be adapted from a standard extraction form used by
CDAG. These data will then be entered into the Cochrane Col-
laboration software (ReviewManager 5.3) for data analysis. The
following data will be extracted: number of participants treated,
route of administration of DHC and comparison, dosage of DHC
and comparison, study design, study duration and length of fol-
low-up, results related to the primary and secondary outcomes,
funding source and conflict of interest of study authors.
When there is information missing from the original studies on
outcomes or other important information, we will contact the
corresponding author via e-mail in order to request additional
data.
Assessment of risk of bias in included studies
The ’Risk of bias’ assessment of RCTs in this review will be per-
formed using the criteria recommended in the Cochrane Hand-
book (Higgins 2011). The recommended approach for assessing
risk of bias in studies included in a Cochrane Review is a two-
part tool that addresses seven specific domains, namely sequence
generation and allocation concealment (selection bias), blinding
of participants and providers (performance bias) blinding of out-
come assessors (detection bias), incomplete outcome data (attri-
tion bias), selective outcome reporting (reporting bias) and other
sources of bias. The first part of the tool involves describing what
was reported to have happened in the study. The second part of
the tool involves assigning a judgment relating to the risk of bias
for that entry, in terms of low, high or unclear risk. To make these
judgments we will use the criteria indicated in theCochrane Hand-
book, adapted to the addiction field. See Table 1 for details.
The domains of sequence generation and allocation concealment
(avoidance of selection bias) will be addressed in the tool by a
single entry for each study.
Blinding of participants, personnel and outcome assessors (avoid-
ance of performance bias and detection bias) will be considered
separately for objective outcomes (e.g. drop out, use of substance
of abuse measured by urinalysis, subjects relapsed at the end of
follow up, subjects engaged in further treatments) and subjective
outcomes (e.g. duration and severity of signs and symptoms of
withdrawal, patient self-reported use of substance, side effects, so-
cial functioning as integration at school or at work or in family
relationships).
Incomplete outcome data (avoidance of attrition bias) will be con-
sidered for all outcomes except for treatment drop out, which is
very often the primary outcome measure in trials on addiction.
Grading of evidence
We will assess the overall quality of the evidence for the primary
outcome using theGrading of Recommendation, Assessment,De-
velopment andEvaluation (GRADE) system. TheGRADEWork-
ing Group developed a system for grading the quality of evidence
(GRADE 2004; Guyatt 2008; Guyatt 2011) which takes into ac-
count issues not only related to internal validity but also to exter-
nal validity, such as directness, consistency, imprecision of results
and publication bias. The ’Summary of findings’ tables present
the main findings of a review in a transparent and simple tabular
format. In particular, they provide key information concerning the
quality of evidence, the magnitude of effect of the interventions
examined and the sum of available data on the main outcomes.
TheGRADE systemuses the following criteria for assigning grades
of evidence:
• High: We are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: We are moderately confident in the effect
estimate: The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low: Our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect.
• Very low: We have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
Grading is decreased for the following reasons:
• Serious (-1) or very serious (-2) limitation to study quality.
• Important inconsistency (-1).
• Some (-1) or major (-2) uncertainty about directness.
• Imprecise or sparse data (-1).
• High probability of reporting bias (-1).
Grading is increased for the following reasons:
• Strong evidence of association - significant relative risk of >
2 (< 0.5) based on consistent evidence from two or more
observational studies, with no plausible confounders (+1).
• Very strong evidence of association - significant relative risk
of > 5 (< 0.2) based on direct evidence with no major threats to
validity (+2).
• Evidence of a dose response gradient (+1).
• All plausible confounders would have reduced the effect
(+1).
Only the primary outcomes will be included and graded in the
’Summary of findings’ table (retention in treatment, abstinence
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from illicit opiates following detoxification, abstinence from il-
licit opiates following maintenance or substitution therapy or seri-
ous adverse events) for DHC compared to methadone, buprenor-
phine, LAAM or morphine.
Measures of treatment effect
The outcomes of the experimental and control groupswill be com-
pared at follow-up appointments. For dichotomous data, risk ra-
tios (with 95% confidence intervals (CIs)) will be calculated. For
continuous data, the mean difference (MD) will be calculated,
with 95% CIs. In the case of continuous data, the standardised
mean difference (SMD) will be the treatment measure used, again
with 95% CIs if the outcomes are measured with different tools
(Higgins 2011). This is only expected to be a possibility for self-re-
ported primary outcomes (abstinence) and any optional secondary
outcomes (such as measures of physical health that may be linked
to substance use e.g. dental problems, gastro-intestinal problems
and tremors or shakes, engagement in illegal activity).
Unit of analysis issues
If included studies have more than one intervention group, sim-
ply entering each comparison in a meta-analysis may lead to the
error of double counting (Higgins 2011). In this case, we will ei-
ther combine groups to allow single comparisons, set up separate
analyses or perform subgroup analyses (if possible) and deselect
the calculation of overall totals to count the participants that were
randomised and not the number of treatment attempts provided.
Dealing with missing data
We will contact the original investigators of research studies to re-
quest any missing data (including outcomes, summary data, indi-
viduals and study-level characteristics) by email. If we are not able
to obtain missing data from the original investigators, we will need
to decide whether the data are missing at random (not related to
the actual data) or notmissing at random (related to the actual data
such as due to participant drop out). When study data are assumed
to be missing at random, only the available data will be analysed.
Where there seems to be a significant amount of missing data, the
possible effects of this on the review’s findings will be addressed in
the Discussion section. If data are not missing at random, it will
be assumed that the participants that dropped out at follow-up are
continuing to use illicit opiates. However, this assumption will be
tested with a sensitivity analysis, which will be monitored by one
of the authors who has a background in statistical analysis.
Assessment of heterogeneity
If more than one study is found and included in the review, we
will check for heterogeneity across the studies. Chi² (X²) and I²
statistical tests will be used to assess if observed differences in study
results occur by chance alone or if these differences are estimates
beyond chance. If the P value for the Chi² test is 0.10 or lower,
and the I² is 50% or more, this indicates a potential problem with
heterogeneity (Higgins 2011).
Assessment of reporting biases
If there are more than 10 included studies in the meta-analysis,
we will consider the risk of publication bias by examining the
symmetry of funnel plots. If any funnel plots are asymmetrical,
these will be further explored, but this is not always indicative of
publication biases (Higgins 2011).
In addition, when there seems to be selective outcome reporting,
we will contact the authors of the relevant studies to request addi-
tional information.
Data synthesis
We will first summarise the main findings of the included studies,
before we decide whether studies are appropriate formeta-analysis,
namely if there two or more individual trials with comparable
intervention methods and outcomes.
Given the heterogeneity of drug-using populations, as well as the
fact that often intervention types are very different, we will use the
random-effectsmodel for analysis. If there ismore thanone follow-
up period for single studies, separate analyses will be performed
on the different follow-up periods. This will be short-term (one
month or less), medium-term (two to six months) and long-term
(seven months or more) follow-up, Where meta-analysis is not
possible, we will report the findings narratively in the body of the
review.
Subgroup analysis and investigation of heterogeneity
Subgroup analysiswill only be possible if there are enough included
studies that have large-enough sample sizes. These analyses may
include:
• Age (16 to 17 year olds versus 18 years and over).
• Treatment history (first treatment attempt versus previous
treatment attempts for opiates).
• Mode of illicit opiate use (injection versus other).
Sensitivity analysis
We will explore the effects of risk of selection bias by conducting
the meta-analysis twice if possible, with the second meta-analysis
excluding studies rated as high risk of allocation concealment and
sequence generation. This will only take place if there are enough
studies to conduct a meta-analysis, and only for the primary out-
come (treatment retention, abstinence, serious adverse events).
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A D D I T I O N A L T A B L E S
Table 1. Criteria for ’Risk of bias’ assessment
Item Judgement Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation
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Table 1. Criteria for ’Risk of bias’ assessment (Continued)
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal al-
location: central allocation (including telephone, web-based, and phar-
macy-controlled randomisation); sequentially-numbered drug containers
of identical appearance; sequentially numbered, opaque, sealed envelopes
High risk Investigators enrolling participants could possibly foresee assignments
because one of the following method was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3. Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding;
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
4. Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers ensured and unlikely that the
blinding could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
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Table 1. Criteria for ’Risk of bias’ assessment (Continued)
unclear risk Insufficient information to permit judgement of low or high risk
5. Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
6. Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
7. Incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or drop out
Low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes
comparedwith observed event risk not enough tohave a clinically-relevant
impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference inmeans or
standardised difference in means) among missing outcomes not enough
to have a clinically relevant impact on observed effect size;
Missing data have been imputed using appropriate methods
All randomised patients are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across in-
tervention groups;
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically-relevant
bias in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough to
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Table 1. Criteria for ’Risk of bias’ assessment (Continued)
induce clinically-relevant bias in observed effect size;
‘As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop out not reported for each group)
8. Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way;
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)
High risk Not all of the study’s pre-specified primary outcomes have been reported;
One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not pre-specified;
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
Unclear risk Insufficient information to permit judgement of low or high risk
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
ID Search
#1 (dihydrocodeine or Codhydrin or codhydrine or codicontin or cohydrin or dehacodin or df118 or “dh codeine” or “di-hydrin”
or didrate or dihydrin or dihydroneopine or drocode or hydrocodeine or hydrocodin or nadein or nadeine or napacodin or
novicodin or paracodein or paracodin or parzone or rapacodin or remedacen or “tiamon mono”):ti,ab,kw (Word variations
have been searched)
#2 MeSH descriptor: [Opioid-Related Disorders] explode all trees
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(Continued)
#3 MeSH descriptor: [Substance Abuse, Intravenous] explode all trees
#4 MeSH descriptor: [Substance Withdrawal Syndrome] explode all trees
#5 ((opiate* or opioid* or narcot* or heroin* or drug or substance) and (abstin* or abstinen* or abus* or addict* or depend* or
detoxify* or desintoxi* or disintoxi* or disintossi* or overdos* or intoxicat* or withdraw* or relaps*)):ti,ab
#6 #2 or #3 or #4 or #5
#7 #1 and #6
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